Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University)

人源化抗CD19和CD20双特异性CAR-T细胞疗法（福建医科大学）

Report date: 2022/07/04 19:38:02

Base Information

Drug NameHumanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University)
Drug Alias NameAutologous humanized anti-CD19 and anti-CD20 dual specific CAR-T CellsCD19/CD20 bispecific CAR-T cells
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD20
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFujian Medical University
China Registration ClassN/A

Develop Information

Active CompaniesFujian Medical University
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A